Idalopirdine granted Fast Track Designation by U.S. Food and Drug Administration (FDA) (H Lundbeck A/S)

(Source: H Lundbeck A/S) Designation provides the opportunity for more frequent interactions with FDA during clinical development and potential eligibility for priority review Valby, 2016-07-07 15:00 CEST (GLOBE NEWSWIRE) -- H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Development & Commercialization, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the investigational agent idalopirdine for the treatment of mild to moderate Alzheimer's disease. Idalopirdine is a selective 5HT6 receptor antagonist with a different hypothesized mechanism of action than currently available Alzheimer's medications. Notably, a focus on the 5-HT6...